( ARTG ) Ultomiris is indicated:, for the treatment of patients with Paroxysmal Nocturnal Haemoglobinuria (PNH), for the treatment of patients with Atypical Haemolytic Uraemic Syndrome (aHUS), as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive., for the treatmen

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-

OTC

HealthdirectFree Australian health advice you can count on.

INN: X

Available in:

🇩🇪🇬🇧

Form

—

Dosage

—

Route

—

Storage

—

About This Product

Manufacturer

Alexion Pharma GmbH (CH)

ATC Code

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.